Download PDF
CC BY-NC-ND 4.0 · Indian J Plast Surg 2023; 56(04): 350-356
DOI: 10.1055/s-0043-1771294
Original Article

Non-COVID-19 Cutaneous Mucormycosis from a Plastic Surgical Perspective

Vimalendu Brajesh
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Sneha Sharma 
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Aditya Aggarwal 
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Sukhdeep Singh
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Sanjay Mahendru
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Hardeep Singh
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Ankit Jain
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Rahul Jain
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
,
Rakesh Kumar Khazanchi
1   Department of Plastic, Aesthetic and Reconstructive Surgery, Medanta – The Medicity, Gurugram, Haryana, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Cutaneous mucormycosis is a rare and fulminant infection associated with high mortality. Plastic surgeons come across this infection in the settings of road traffic accidents, surgical site infections, and as a secondary infection with underlying bacterial soft tissue infections. Due to this infection's rarity and aggressive course, it is essential to initiate prompt multidisciplinary management at the first presentation. With this study, we aim to present a protocol for managing the condition.

Methods This is a retrospective observational study of patients with cutaneous mucormycosis managed at a tertiary care hospital from January 1, 2016 to November 30, 2022 excluding patients with mucormycosis who tested positive for coronavirus disease 2019.

Results Of 24 patients, 22 were males, and most were in the age group of 41 to 60 years. Sixteen patients survived and five out of eight deceased had comorbidities, six presented primarily without prior debridement, and six had trunk involvement.

Conclusion A high index of clinical suspicion is necessary for early diagnosis and management of patients with invasive cutaneous mucormycosis. A multidisciplinary approach with appropriate medical and surgical management can improve outcomes in cases that otherwise carry a high mortality rate.

Keywords

mucormycosis - fungal infection - cutaneous mucormycosis - invasive cutaneous mucormycosis

Ethical Approval

Ethics committee approval obtained from the institutional ethics committee.


Authors' Contributions

All the authors were involved in the conception of the work, data collection, analysis, and interpretation and throughout the process of the drafting and revision of the manuscript.




Publication History

Article published online:
28 July 2023

© 2023. Association of Plastic Surgeons of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Losee JE, Selber J, Vega S, Hall C, Scott G, Serletti JM. Primary cutaneous mucormycosis: guide to surgical management. Ann Plast Surg 2002; 49 (04) 385-390
    CrossrefPubMedSearch in Google Scholar
  • 2 Castrejón-Pérez AD, Welsh EC, Miranda I, Ocampo-Candiani J, Welsh O. Cutaneous mucormycosis. An Bras Dermatol 2017; 92 (03) 304-311
    CrossrefPubMedSearch in Google Scholar
  • 3 Roden MM, Zaoutis TE, Buchanan WL. et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (05) 634-653
    CrossrefPubMedSearch in Google Scholar
  • 4 Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54 (Suppl 1, Suppl 1): S8-S15
    CrossrefPubMedSearch in Google Scholar
  • 5 Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel) 2019; 5 (01) 26
    Search in Google Scholar
  • 6 Wirth F, Perry R, Eskenazi A, Schwalbe R, Kao G. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. J Am Acad Dermatol 1997; 36 (2 Pt 2): 336-341
    CrossrefPubMedSearch in Google Scholar
  • 7 Cocanour CS, Miller-Crotchett P, Reed II RL, Johnson PC, Fischer RP. Mucormycosis in trauma patients. J Trauma 1992; 32 (01) 12-15
    CrossrefPubMedSearch in Google Scholar
  • 8 Lehrer RI, Howard DH, Sypherd PS. et al. Mucormycosis. Ann Intern Med 1980; 93 (01) 93-108
    CrossrefPubMedSearch in Google Scholar
  • 9 Wang K, Jacinto J, Davis A, Hetman A, Kumar A. A case report: utilization of topical amphotericin in postoperative mucormycosis. HCA Healthcare Journal of Medicine 2021; 2 (03) 5
    CrossrefPubMedSearch in Google Scholar
  • 10 Cornely OA, Alastruey-Izquierdo A, Arenz D. et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19 (12) e405-e421
    CrossrefPubMedSearch in Google Scholar
  • 11 Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47 (04) 503-509
    CrossrefPubMedSearch in Google Scholar
  • 12 Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48 (12) 1743-1751
    CrossrefPubMedSearch in Google Scholar